Nifedipine and metoprolol in unstable angina infarction but characteristic of myocardial ischaemia-anginal pain at rest not severe enough to suggest myocardial infarction, combined with changing electrocardiographic findings compatible with ischaemia but not directly diagnostic of infarction. This syndrome is usually called unstable angina. Patients with this diagnosis at admission to the coronary care unit may be in the process of sustaining a myocardial infarction. Alternatively, the infarction may not yet have occurred, and the patient should be considered at risk for recurrent and possibly irreversible ischaemia. [1] [2] [3] After initial pain relief the aims of early treatment are the prevention of recurrent ischaemia or myocardial infarction and the restoration of a stable condition. Calcium antagonists and / blockers are among the agents that have been advocated as being useful in this respect.48 Calcium antagonists are thought to increase oxygen supply by coronary vasodilation and P blockers are assumed to reduce oxygen demand by decreasing heart rate and myocardial contractility.9 10 However, /3 blockers have also been implicated as a potential cause of increased coronary vasomotor tone1' 12 and calcium antagonists in the coronary steal phenomenon.9 13 Furthermore, several cases of severe congestive heart failure have been reported in patients treated with both drugs. 14 15 In 1980 the Holland Interuniversity Nifedipine/ metoprolol Trial (HINT) research group initiated a randomised, double blind, placebo controlled, multicentre trial to assess the role of calcium antagonists and P blockers in the treatment of unstable angina. At that time this role had not been defined. 16 The objective of the trial was to determine whether nifedipine (a calcium antagonist) and metoprolol (a P blocker) could prevent recurrence of ischaemia or progression to myocardial infarction when given either alone or in combination to patients diagnosed as having unstable angina at admission to the coronary care unit. The trial was confined primarily to an observation period of 48 30 October 1984 enrolment was discontinued because an interim analysis suggested that the risk of myocardial infarction was higher in patients assigned to nifedipine than in patients treated with the other trial medications. The data on which this decision was based are reproduced in appendix I. Both Bayer and Hassle and the Dutch health authorities were informed of the decision but not of the actual data. This report deals with the main findings on the efficacy of nifedipine and metoprolol in preventing recurrent ischaemia and myocardial infarction in the 515 patients who were eventually available for analysis.
Patients and methods

ORGANISATION
Eight university and three non-university cardiology departments participated. Before the start of the trial the protocol was approved by the Scientific Council of the Interuniversity Cardiology Institute and by the principal investigators of participating nonuniversity hospitals (together they formed the Executive Committee) and by the ethics committees at each participating centre. A Policy Advisory Board of acknowledged experts in related fields, not otherwise associated with the trial, also approved the protocol and adopted the task of progress monitoring. Until the decision was taken to discontinue the trial only this board was informed of the interim results.
Data were processed by the Clinical Epidemiology
Unit of the Thoraxcentre in Rotterdam, which also provided overall coordination. Its Those patients for whom an unequivocal protocol violation occurred before the start of trial medication were excluded from analysis. These exclusions were applied retrospectively by the Classification Committee. Patients were retained, however, if the committee disagreed with the attending physician's assessment of qualifying ST-T abnormalities or changes. Treatment effects were assessed in terms of the occurrence of the two outcome events defined above. In accordance with the protocol, patients classified as having pre-randomisation myocardial infarction were excluded from this assessment. Treatment effects were expressed as the ratio of the rate of the respective outcome event observed in patients allocated to a specific index trial medication to that observed in patients allocated to a specific reference trial medication. For instance, the effect of nifedipine relative to placebo is the rate of the outcome event in the nifedipine group divided by that in the placebo group. Thus a rate ratio of one indicates that nifedipine has no effect relative to placebo. A rate ratio of < 1 points to a preventive effect and a rate ratio > 1 to a detrimental effect. The 95% confidence intervals of the rate ratio estimates are also given.
We used a composite logistic prediction function to determine which baseline characteristics were independently related to the risk of recurrent ischaemia or myocardial infarction within 48 hours.
The baseline risk of recurrent ischaemia or myocardial infarction within 48 hours (that is, the probability that such an event would occur) was'estimated for each patient separately given individual baseline characteristics and the prediction function. Patients were subsequently divided into three subgroups of low, medium, and high risk.
In the analysis we found that despite random 403 allocation, trial medication groups differed in terms of the distribution of baseline risk. To adjust for this, relative treatment effects, as defined above, were estimated as weighted averages of risk subgroup specific effects. Full details of the analytic methods are given in appendix II.
STUDY SIZE REQUIREMENTS
The protocol stated that trial treatments were to be evaluated in terms Figure 1 shows that a violation of the admission protocol occurred in 131 patients; these cases were excluded. Another 22 patients classified as having pre-randomisation myocardial infarction were left out from trial medication assessment. In 82% of the 515 remaining patients the treating physician's judgement on qualifying ST-T abnormalities or changes was independently confirmed by the Classification Committee. Table 4 shows the number of pre-randomisation infarctions by trial medication group. Also shown are the outcome event rates for patients without prerandomisation infarction, both overall and according to stratum of baseline risk for recurrent ischaemia or myocardial infarction within 48 hours. The directions of the differences between the trial medication groups were consistent over the risk strata. In patients not on previous maintenance treatment with a ,B blocker who were treated with nifedipine both event rates were higher than the corresponding ones for those on placebo. This was also true for Q wave infarctions. On the other hand, in patients on metoprolol or on the combination, event rates tended to be lower than the rates for those on placebo. In patients who were already on a /3 blocker, the nifedipine group tended to have lower event rates than the placebo group. Table 5 gives the estimated relative effects 
Nifedipine and metoprolol in unstable angina angioplasty or bypass surgery are now increasingly offered, with good results.2' It is unlikely, however, that the more general use of these procedures will have had any great effect on the clinical spectrum because such procedures are usually restricted to patients in whom chest pain persists despite maximal pharmacological treatment. In such cases angioplasty or bypass surgery may prevent the occurrence of myocardial infarction. Of the infarctions in the present trial only the later ones could have been prevented in this way, and there were only a few of these.
EFFECTS OF TRIAL MEDICATION
On the basis of an interim analysis enrolment in the present trial was discontinued (appendix I). This was because continuation ofnifedipine monotherapy trial medication was considered to be unethical and, secondly, because there were only small differences between the other groups. The final data as presented here essentially accord with the interim data that led to this decision (tables 4 and 5, and appendix I).
Although the series is large, the trial medication groups are rather small. In a randomised trial with small groups the results may indicate differences in the baseline risk between the groups. Table 2 shows that this was indeed the case. We used an approach developed for non-experimental epidemiological studies22 to impose risk stratification based on a composite logistic function of relevant baseline characteristics on our study group and we have expressed trial medication effects as weighted averages of stratum specific rate ratios. This approach ensures that the estimation of trial medication effect becomes independent ofthe distribution of baseline risk in the groups that are compared. The use of 95% confidence intervals for the rate ratios so obtained provides a better indication of the statistical strength of evidence than the customary significance levels (p values).23
Patients with a pre-randomisation myocardial infarction are no longer at risk of the defined outcome events. Therefore, we excluded these patients before we assessed the trial medication effects. To allow for effect analyses based on other principles the number of pre-randomisation infarctions is also given per treatment group (table 4) .
Of all the treatments studied only the addition of nifedipine to previous maintenance treatment with a P blocker was clearly beneficial. None of the other trial regimens came out as being unequivocally effective. Furthermore, there was a worrying trend towards an increased risk for myocardial infarction in patients assigned to nifedipine alone. What is the explanation for these findings? 409 We postulate that when nifedipine is given to patients whose condition has become unstable despite maintenance treatment with a ,B blocker coronary spasm may play a larger role than it does in patients not on # blockade. This would explain the efficacy of additional treatment with a coronary spasmolytic agent such as nifedipine.
We do not believe that the apparent lack of effect of the other trial medications is caused by the selection of already stabilised patients, which would lead to too few potential outcome events. The event rate of recurrent ischaemia or myocardial infarction within 48 hours was considerable and accorded with the a priori design assumptions. Nevertheless, the confidence intervals given in table five do not exclude the possibility that relevant trial medication effects were missed. We believe that the most likely explanation lies in the particular clinical situation that this trial was designed to examine. The trial design assumed that neither ischaemia nor necrosis was present after eligibility had been established. We realised that because there are no specific early electrocardiographic signs of necrosis inclusion of some patients in whom myocardial infarction was already evolving would be unavoidable. Although we appreciated that enzyme concentrations increase within hours of the onset of myocardial infarction, we decided to exclude patients from trial medication assessment only if enzymes were already significantly raised at randomisation. This The reason why nifedipine monotherapy increases the risk of progression to myocardial infarction cannot be determined from our data. The nifedipine results may be a chance finding. On the other hand, they virtually exclude a major preventive effect of nifedipine used in this way for this indication. We do not believe that nifedipine's postulated influence on the release of enzymes26 explains this finding-there were more Q wave infarcts in the nifedipine monotherapy group than in the placebo group (table 4) . Relative to placebo, nifedipine did not raise the heart rate substantially but it reduced blood pressure. It is possible therefore that the temporary rise in heart rate in combination with a decrease in blood pressure, which has been observed before,27 plays a role.
Nifedipine is generally accepted to be of particular value in patients with ST elevation during pain. A hundred and one patients had these features before entry (table 1) . Subgroup analysis did not show that these patients especially benefited from nifedipine alone.
COMPARISON WITH OTHER STUDIES
In another trial for which patients were selected at hospital admission treatment with four 20 mg doses of nifedipine given over 24 hours was compared with placebo.28 Eligibility for the trial, however, required more prolonged chest pain than in the present trial and patients with electrocardiographic evidence of acute infarction were not excluded. Patients were later stratified into either acute or threatened myocardial infarction groups on the basis of the presence or absence of increased enzyme concentrations and Q waves at randomisation. The group with threatened myocardial infarction resembled the patients that we studied. The rate of progression to myocardial infarction, 75% after 24 
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The HINT Research Group Table 6 Indicator variables (with coefficients and *Number of patients in whom the property considered was present.
The baseline risk function was obtained by setting the variables representing the patient's actual trial medication to values representing treatment with placebo. Table 6 shows the variables that were eventually retained in the model with their coefficients and standard errors.
STRATIFIED ANALYSIS
Patients were ranked on the basis of their calculated baseline risk and were subsequently divided into three strata of low, medium, and high risk. The cutoffpoints were chosen so that each stratum contained an equal number of patients in whom recurrent ischaemia or myocardial infarction within 48 hours had occurred. We calculated rate ratios as weighted averages of the stratum specific rate ratios for each trial medication comparison and for each variable of interest,3' and thus adjusted for variability of the baseline risk. Confidence limits were calculated accordingly.
